The Big Picture
Friday's headlines sent mixed signals for cannabis and adjacent markets. A high-profile federal push to accelerate psychedelics research and a $50 million allocation for ibogaine grabbed attention, while state regulators and international enforcement actions signaled rising compliance risk.
Why it matters to you: policy momentum at the federal level could create new clinical and commercial pathways over time, but near-term reaction will be driven by how regulators execute on rescheduling, enforcement and market controls.
Market Highlights
Markets were closed on Saturday, April 18. Use the points below to orient yourself heading into the long weekend and into Monday's session.
- Federal action: President Trump signed an executive order on April 18 that fast-tracks psychedelic research and directs $50 million toward ibogaine research, a move that explicitly prioritizes clinical development.
- Consumer trends: Pre-rolls became the largest U.S. cannabis product category in 2025, generating $3.6 billion in revenue and more than 383 million units sold, according to Headset data reported by Custom Cones USA.
- State pricing and supply: In Massachusetts the Cannabis Control Commission approved a four-month cultivation licensing freeze starting June 16 to address falling prices, with average flower prices reported near $14 for an eighth.
- Regulatory enforcement: Colorado announced plans to crack down on illegal hemp product sales citing risks to public safety and tax frameworks, while kratom and other botanicals are facing growing bans and scrutiny.
- Sector tickers to watch heading into Monday: $MSOS, $TCNNF, $GTBIF, $CURLF, $TLRY. Check Friday, April 17 closes for each before making decisions.
Key Developments
Federal Psychedelics Push and Research Funding
Two major outlets reported that the White House signed an executive order on April 18 to accelerate access to psychedelics for patients and expand clinical research. The order includes a $50 million allocation for ibogaine research and directs agencies to prioritize trials for psilocybin, MDMA and other compounds.
Analysts and advocacy groups like MAPS have expressed cautious optimism, noting the move creates a clearer federal pathway for clinical work. Implementation and timeline remain uncertain, however, and rescheduling and regulatory frameworks will determine commercial implications.
State-Level Enforcement and Market Integrity Measures
Colorado regulators announced a crackdown on illegal hemp-product retailers, warning of public-safety and tax-revenue risks. That action reflects a larger emphasis on market integrity and could benefit licensed operators if enforcement reduces illicit competition.
At the same time, kratom and related botanicals are coming under tougher scrutiny in multiple jurisdictions. Those enforcement trends raise questions about the consistency of drug policy reform across product classes.
Supply Moves: Massachusetts Freeze and International Risks
The Massachusetts Cannabis Control Commission voted to impose a four-month moratorium on new cultivation licenses starting June 16, aimed at stemming price declines. That pause could stabilize local wholesale prices if supply growth slows.
Internationally, reporting from Spain highlights rising enforcement and safety incidents linked to home extraction and solvent use, underscoring cross-border risks for companies operating in multiple regulatory environments.
What to Watch
Expect a busy stretch of policy and data-driven catalysts next week that could tilt sentiment. You should monitor the following items closely.
- DOJ and rescheduling process, timing and draft rules, after President Trump publicly called out the department for slow-walking implementation of his prior order; execution risk is high and could affect federally focused plays.
- Implementation details from the executive order on psychedelics, including agency timelines, grant programs and trial eligibility, which will influence biotech and clinical-stage names tied to new therapeutics.
- State enforcement activity in Colorado and other markets, and whether crackdowns reduce illicit supply or push consumers to unregulated channels, affecting retail comps and tax revenue trends.
- Massachusetts licensing freeze effects on wholesale prices and local producers; will it ease downward price pressure or just delay capacity growth?
- Product trends and category rotation; the pre-roll category now accounts for sizable dollars and units, suggesting companies with strong roll-and-pack margins could outperform on unit economics.
- Ticker watch list you should track: $MSOS, $TCNNF, $GTBIF, $CURLF, $TLRY, plus clinical-stage psychedelics names as details emerge.
What questions should you be asking? How quickly will federal agencies move, and will state-level enforcement be consistent across markets? Keep those two front of mind.
Bottom Line
- Federal policy change on psychedelics is a headline-positive development, but outcomes depend on agency implementation and rescheduling mechanics.
- State-level enforcement and licensing freezes introduce supply-side variables that could support prices in targeted markets, while raising compliance costs.
- Category dynamics favor pre-rolls after $3.6 billion in 2025 sales, signaling product-led growth opportunities for operators focused on roll-and-pack economics.
- International and botanical crackdowns show that regulatory risk is not limited to U.S. policy; cross-border operators should expect variation and enforcement surprises.
- Given mixed signals, analysts note selective positioning and close monitoring of policy timelines, regulatory actions and next-week data will be critical.
FAQ Section
Q: How will the federal psychedelics order affect cannabis companies? A: The order primarily targets clinical research for psychedelics rather than adult-use cannabis, but it could shift investor attention and capital toward therapeutic-focused biotech and create regulatory precedents over time.
Q: Will Massachusetts' cultivation freeze raise prices statewide? A: The freeze aims to slow capacity growth and could reduce downward pressure on wholesale prices if demand remains steady, though outcomes depend on enforcement and market responses.
Q: What should you watch first on Monday? A: Start with DOJ and agency guidance on rescheduling, any follow-up from the White House on psychedelic implementation, and weekend enforcement headlines from state regulators that may affect Monday morning sentiment.